"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...
BioAge Labs (BIOA) announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback